⚕ GalenOps field
←

SITE010-0181

completed

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE010 (ESP) · Dr. Silva
consented 2022-09-24

AEs
6
Serious
1
Dropout signal
–

Adverse events

mild assessed

Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-11-29 (study day 49); relationship: N

mild assessed

Grade 1 Fatigue — outcome: RECOVERED/RESOLVED; onset 2023-02-27 (study day 139); relationship: N

mild assessed

Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-08-28 (study day 321); relationship: not assessed

moderate assessed

Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-10-21 (study day 375); relationship: N

severe serious assessed

Grade 4 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2024-05-10 (study day 577); relationship: Y; serious criteria: life-threatening

mild assessed

Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2024-08-15 (study day 674); relationship: N

Data queries

No data queries.